PharmaMar reports cancer drug results
Spanish biopharmaceutical company PharmaMar presented the results of successful preclinical studies on its novel drug candidates Aplidin (plitidespsin, Marketletters passim) and PM02734 at the Congress of the American Association of Cancer Research, in Chicago.
The firm says that results from the studies form the basis for rational development models for both drugs, and Phase III trials in the case of Aplidin. The drugs will seek indications for the treatment of solid tumors and hematological malignancies.
The results covered in vitro and in vivo studies of Aplidin as a single agent and in combination with other chemotherapeutic compounds, as well as PM02734 in combination with similar other treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze